Clinical trial
Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow…
NCT00002943 · Wake Forest University Health Sciences, Other · Completed
Key facts
| NCT number | NCT00002943 |
|---|---|
| Title | Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer |
| Official title | High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Bone Marrow Transplantation for Relapsed and Refractory Germ Cell Cancer: A Phase II Pilot Study |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Procedure |
| Interventions | carboplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation |
| Enrollment | 11 |
| Start date | Feb 1, 1993 |
| Primary completion | Oct 1, 2003 |
| Completion | Aug 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 10, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: